TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30011303

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) usage
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Middle subjective social status (structural determinant)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Hope (intermediary determinant)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Health anxiety
Number of subjects: 1500
Study: 25944813

Group type: EXPERIMENTAL
Intervention: 50 mg dexketoprofen in 50 ml saline
Number of subjects: 224

Group type: COMPARATOR
Intervention: 50 ml saline as placebo
Number of subjects: 224
Study: 25120329

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 50
Study: 23206408

Group type: EXPERIMENTAL
Intervention: Low-dose Cyclosporine A (trough concentrations 130 < CsA < 200 μg/L, n=47)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard-dose Cyclosporine A (trough concentrations 200 < CsA < 300 μg/L, n=48)
Number of subjects: 95
Study: 20933482

Group type: EXPERIMENTAL
Intervention: MD+glucose (2:1 ratio)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MD+galactose (2:1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MD+fructose (2:1)
Number of subjects: 10
Study: 18608200

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 9995

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 9995

Group type: EXPERIMENTAL
Intervention: Valsartan (Lowest Quartile)
Number of subjects: 9995

Group type: COMPARATOR
Intervention: Amlodipine (Lowest Quartile)
Number of subjects: 9995

Group type: EXPERIMENTAL
Intervention: Valsartan (Second Quartile)
Number of subjects: 9995

Group type: COMPARATOR
Intervention: Amlodipine (Second Quartile)
Number of subjects: 9995

Group type: EXPERIMENTAL
Intervention: Valsartan (Third Quartile)
Number of subjects: 9995

Group type: COMPARATOR
Intervention: Amlodipine (Third Quartile)
Number of subjects: 9995

Group type: EXPERIMENTAL
Intervention: Valsartan (Fourth Quartile)
Number of subjects: 9995

Group type: COMPARATOR
Intervention: Amlodipine (Fourth Quartile)
Number of subjects: 9995

Group type: EXPERIMENTAL
Intervention: Valsartan vs Amlodipine (Fourth Quartile)
Number of subjects: 9995

Group type: EXPERIMENTAL
Intervention: Valsartan vs Amlodipine (Treatment Benefit)
Number of subjects: 9995
Study: 15531937

Group type: EXPERIMENTAL
Intervention: Primary Direct Stenting (PDS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endoscopic Atraumatic Coronary Artery Bypass (EACAB)
Number of subjects: 100
Study: 10903213

Group type: EXPERIMENTAL
Intervention: Cylexin (CY-1503) administered on the day of surgery
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cylexin (CY-1503)
Number of subjects: 51
Study: 9071250

Group type: EXPERIMENTAL
Intervention: Telephone-based problem-solving therapy sessions conducted by graduate student therapists supervised by a psychiatrist.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison group (not specified what intervention was used).
Number of subjects: 29
Study: 12959286

Group type: EXPERIMENTAL
Intervention: Hospital meal provision plus supplemental feeding with Build-up (Nestle) and Maxijul (SHS Ltd)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hospital provision alone
Number of subjects: 14
Study: 3530151

Group type: EXPERIMENTAL
Intervention: ECMO in Phase I (50 moribund patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ECMO in Phase II (30 high risk patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ECMO in Phase III (20 moderate to high risk patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ECMO for persistent fetal circulation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ECMO for congenital diaphragmatic hernia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ECMO for meconium aspiration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ECMO for respiratory distress syndrome
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ECMO for sepsis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follow-up outcomes
Number of subjects: 100
Study: 30541346

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (12 weeks, 3 sessions/week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 22
Study: 28791976

Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram bulk-fill composite resin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Universal nano-hybrid resin composite (Tetric EvoCeram)
Number of subjects: 34
Study: 27521437

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 484

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 484
Study: 24356922

Group type: EXPERIMENTAL
Intervention: Oral oxycodone plus intravenous acetaminophen
Number of subjects: 153

Group type: COMPARATOR
Intervention: Intravenous morphine sulfate
Number of subjects: 153
Study: 23042034

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (onabotulinumtoxinA) injection (160 U) into biceps brachii
Number of subjects: 19

Group type: COMPARATOR
Intervention: Before injection
Number of subjects: 19
Study: 19503784

Group type: EXPERIMENTAL
Intervention: Degarelix (240 mg initial dose followed by 80 mg or 160 mg monthly injections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide (GnRH agonist)
Number of subjects: 0
Study: 17498195

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15471520

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer restoration (Vitremer, 3M)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Amalgam or composite restoration (control)
Number of subjects: 83
Study: 11220888

Group type: EXPERIMENTAL
Intervention: Quadropril (6 mg once daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amlodipine (initially 5 mg/day, increased to 10 mg/day if necessary)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amlodipine (5 mg and 10 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quadropril
Number of subjects: 80
Study: 9750602

Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine 30 mg immediately after SB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (1 mL of intramuscular saline) immediately after SB
Number of subjects: 20
Study: 8458358

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined treatment (Nifedipine + Propranolol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baseline Holter monitoring
Number of subjects: 50
Study: 3797826

Group type: EXPERIMENTAL
Intervention: 10 mg of oral nifedipine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31167860

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleeve gastrectomy
Number of subjects: 0
Study: 30513108

Group type: EXPERIMENTAL
Intervention: Raltegravir-intensified ART
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Standard ART
Number of subjects: 1805
Study: 27938362

Group type: EXPERIMENTAL
Intervention: ao-dake-humi
Number of subjects: 24
Study: 25614338

Group type: COMPARATOR
Intervention: Standard cryoballoon (CB‐S)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Redesigned cryoballoon Arctic Front Advance (CB‐A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Left pulmonary veins (PVs)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Right pulmonary veins (PVs)
Number of subjects: 36
Study: 23940228

Group type: EXPERIMENTAL
Intervention: Project Connect Online (3-hour workshop for hands-on creation of personal Web sites with a follow-up call)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 88
Study: 21158876

Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous (AA) attendance
Number of subjects: 1726
Study: 18212722

Group type: EXPERIMENTAL
Intervention: Active Clinical Observation (ACO)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Outpatient Group (OG)
Number of subjects: 105
Study: 16997680

Group type: EXPERIMENTAL
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Midazolam (0.1 mg/kg)
Number of subjects: 100
Study: 14584565

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FDG uptake ratios with occipital lobe metabolism as covariate reference region
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FDG uptake ratios with white matter metabolism as reference covariate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: General analyses
Number of subjects: 12
Study: 10712324

Group type: COMPARATOR
Intervention: Intravenous augmentation therapy
Number of subjects: 147
Study: 8689423

Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD AraC) 2 x 10 mg/m2 sc, day 1-14 plus interleukin-3 (IL-3) once daily sc, day 8-21 at varying doses (1.0, 2.5, 5.0, and 10.0 micrograms/kg)
Number of subjects: 31
Study: 1364935

Group type: EXPERIMENTAL
Intervention: Enteric coated naproxen (Nycopren)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Standard naproxen
Number of subjects: 348
Study: 31856049

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone (placebo group)
Number of subjects: 0
Study: 29137628

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) pre-injection 4 mL/kg 7.5% HS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) pre-injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (NS group) pre-injection 4 mL/kg isotonic saline
Number of subjects: 120
Study: 26637580

Group type: EXPERIMENTAL
Intervention: Long-term low-dose azithromycin (250 mg daily for 3 months) plus standard conventional treatment (fluticasone nasal spray plus normal saline solution irrigation)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard conventional treatment (fluticasone nasal spray plus normal saline solution irrigation)
Number of subjects: 66
Study: 24924416

Group type: EXPERIMENTAL
Intervention: Fulvestrant (500 mg IM days 1, 15, 29, then monthly) plus Vandetanib (100 mg PO OD)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Fulvestrant (500 mg IM days 1, 15, 29, then monthly) plus Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Vandetanib
Number of subjects: 127

Group type: COMPARATOR
Intervention: Fulvestrant plus Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Baseline uNTx (>65 nM BCE/mmol Cr)
Number of subjects: 127
Study: 23767201

Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citicoline
Number of subjects: 0

Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 0
Study: 19463034

Group type: EXPERIMENTAL
Intervention: Group music therapy (10-week project with ten one-hour weekly sessions including song singing, song writing, and improvisation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group music therapy
Number of subjects: 0
Study: 18628615

Group type: EXPERIMENTAL
Intervention: Heparin bridging
Number of subjects: 376

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 376
Study: 16131696

Group type: EXPERIMENTAL
Intervention: 3 mg caffeine . kg(‐1) . d(‐1) (C3)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 6 mg caffeine . kg(‐1) . d(‐1) (C6)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 0 mg caffeine . kg(‐1) . d(‐1) (C0; placebo)
Number of subjects: 59
Study: 12354682

Group type: EXPERIMENTAL
Intervention: Nutrition information about energy density of meals
Number of subjects: 40

Group type: COMPARATOR
Intervention: No nutrition information
Number of subjects: 40
Study: 9987086

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) 0.6 g.kg-1.24 hr-1, N = 14
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal-protein diet (NPD), N = 15
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) during phase II
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal-protein diet (NPD) during phase II
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 7591421

Group type: EXPERIMENTAL
Intervention: Silicon plates with added vitamin E
Number of subjects: 80

Group type: COMPARATOR
Intervention: Simple silicone gel sheets
Number of subjects: 80
Study: 1967730

Group type: EXPERIMENTAL
Intervention: B subunit killed whole‐cell (BS‐WC)
Number of subjects: 62285

Group type: EXPERIMENTAL
Intervention: Killed whole‐cell (WC)
Number of subjects: 62285
Study: 7427409

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg daily for three weeks) with Propranolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg daily for three weeks) with Thiazide diuretics
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo with Propranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo with Thiazide diuretics
Number of subjects: 15
Study: 30803290

Group type: EXPERIMENTAL
Intervention: Intraoperative plus postoperative hemoadsorption therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sole intraoperative hemoadsorption therapy
Number of subjects: 20
Study: 29280118

Group type: EXPERIMENTAL
Intervention: Microecological treatment group
Number of subjects: 198

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 198
Study: 25902320

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 ng•mL with propofol TCI between 2.40 and 4.23 μg•mL (bolus of 1 mg•kg)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 ng•mL with propofol TCI between 2.15 and 2.88 μg•mL (bolus of 0.75 mg•kg)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Propofol fixed at 2 μg•mL with remifentanil TCI between 1.00 to 4.79 ng•mL
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Propofol fixed at 3 μg•mL with remifentanil TCI between 0.72 to 3.19 ng•mL
Number of subjects: 124
Study: 24079288

Group type: EXPERIMENTAL
Intervention: Whole eggs (EGG, n = 20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Egg substitute (SUB, n = 17)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (EGG and SUB)
Number of subjects: 37
Study: 21131862

Group type: EXPERIMENTAL
Intervention: One-third maintenance dose of resistance training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: One-ninth maintenance dose of resistance training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Detraining
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Strength gained during phase 1
Number of subjects: 70
Study: 19750261

Group type: EXPERIMENTAL
Intervention: Aspirin (1.5 g/day, 500 mg every 8 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17520360

Group type: EXPERIMENTAL
Intervention: Attention to breathing instructions
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Shallow breathing instructions
Number of subjects: 43

Group type: COMPARATOR
Intervention: Anti-hyperventilation instructions
Number of subjects: 43

Group type: COMPARATOR
Intervention: Heart rate and skin conductance measures
Number of subjects: 43
Study: 14687740

Group type: EXPERIMENTAL
Intervention: Manual removal of the placenta (n=100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Spontaneous separation of the placenta (n=100)
Number of subjects: 200
Study: 11348713

Group type: EXPERIMENTAL
Intervention: Virosomal vaccine
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Split vaccine
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 285
Study: 9404473

Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam
Number of subjects: 258

Group type: COMPARATOR
Intervention: 100 mg diclofenac
Number of subjects: 258
Study: 8265329

Group type: EXPERIMENTAL
Intervention: Nurse home visitation from pregnancy through second year of the child's life
Number of subjects: 400
Study: 2889397

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 30
Study: 29476542

Group type: EXPERIMENTAL
Intervention: Emollient treatment (specific emollients not detailed)
Number of subjects: 197
Study: 26836747

Group type: EXPERIMENTAL
Intervention: Nickel titanium (NiTi) springs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stainless steel (SS) springs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of NiTi and SS springs
Number of subjects: 40
Study: 25431023

Group type: EXPERIMENTAL
Intervention: Atrial Rhythm Control (ARC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: AF
Number of subjects: 52
Study: 23584615

Group type: EXPERIMENTAL
Intervention: Therapeutic play (TP) during EBRT
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no therapeutic play)
Number of subjects: 19
Study: 20381164

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 0
Study: 19029501

Group type: EXPERIMENTAL
Intervention: Community pharmacist and nurse care intervention including BP wallet card, cardiovascular risk reduction education, hypertension education pamphlet, referral to primary care physician, evidence summary for physician, and 4 follow-up visits over 6 months.
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group received a BP wallet card, pamphlet on diabetes, general diabetes advice, and usual care by their physician.
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Community pharmacist and nurse care intervention for patients with baseline systolic BP greater than 160 mm Hg.
Number of subjects: 227
Study: 16608936

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) for 16 weeks including breathing retraining and exercise
Number of subjects: 40
Study: 12055813

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (100 mg for age 1-3 years or 200 mg for age 4-11 years, twice daily for 3 days)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Albendazole (400 mg single dose)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Praziquantel (25 mg/kg single dose)
Number of subjects: 85
Study: 10480704

Group type: EXPERIMENTAL
Intervention: Non-fasting serum true insulin concentration
Number of subjects: 5550

Group type: EXPERIMENTAL
Intervention: Non-fasting serum glucose > or =6.1 mmol/l at baseline
Number of subjects: 5550
Study: 8983443

Group type: EXPERIMENTAL
Intervention: D‐dimer level detected using semiquantitative method (D‐dimer Latex Test, Diagnostica Stago‐Boehringer Mannheim) before and during treatment.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cells number and composition using light microscope before and during treatment.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: D‐dimer level in tuberculous effusions before treatment.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: D‐dimer level in neoplastic pleural effusion.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: D‐dimer level in blood.
Number of subjects: 33
Study: 1765040

Group type: EXPERIMENTAL
Intervention: Moderate-dose fentanyl (20 micrograms kg-1) combined with isoflurane, nitrous oxide and oxygen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thoracolumbar epidural bupivacaine combined with isoflurane, nitrous oxide and oxygen
Number of subjects: 20
Study: 6604371

Group type: EXPERIMENTAL
Intervention: Neodymium-Yag laser treatment
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Yag laser photocoagulation
Number of subjects: 130
Study: 29274892

Group type: EXPERIMENTAL
Intervention: 45g/day of resistant starch (RS=amylose) for 12 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Amylopectin (Control) for 12 weeks
Number of subjects: 68
Study: 27174694

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 30 U/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 60 U/kg
Number of subjects: 23
Study: 24496072

Group type: EXPERIMENTAL
Intervention: CACE‐Is (n = 91)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Perindopril (part of CACE‐Is)
Number of subjects: 406

Group type: COMPARATOR
Intervention: NoCACE‐I (n = 274)
Number of subjects: 406
Study: 22769569

Group type: EXPERIMENTAL
Intervention: UFT adjuvant therapy (500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by 2-day rest, repeated for 1 year)
Number of subjects: 2024

Group type: EXPERIMENTAL
Intervention: UFT adjuvant therapy
Number of subjects: 2024

Group type: COMPARATOR
Intervention: Observation without any adjuvant treatment
Number of subjects: 2024
Study: 20484482

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 19
Study: 18824368

Group type: EXPERIMENTAL
Intervention: MCABG
Number of subjects: 30

Group type: COMPARATOR
Intervention: CCABG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 30
Study: 15933481

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (25, 50 or 75 mg every 2 weeks)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone
Number of subjects: 439

Group type: COMPARATOR
Intervention: Long-acting risperidone and Placebo
Number of subjects: 439
Study: 12646338

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 615
Study: 10771799

Group type: EXPERIMENTAL
Intervention: Heated humidifier (HH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hygroscopic heat and moisture exchanger (HHME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 0
Study: 8783991

Group type: EXPERIMENTAL
Intervention: Aprotinin (full recommended dose) in group D
Number of subjects: 70

Group type: COMPARATOR
Intervention: No aprotinin in group C
Number of subjects: 70
Study: 1474275

Group type: EXPERIMENTAL
Intervention: BCG 0.1 mg + 6 x 10(8) KML (I)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: BCG 0.1 mg + 5 x 10(7) KML (II)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: BCG 0.1 mg + 5 x 10(6) KML (III)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: BCG 0.1 mg (IV)
Number of subjects: 997

Group type: COMPARATOR
Intervention: Normal saline (V)
Number of subjects: 997